RELYVRIO: payments to doctors
Payments that named RELYVRIO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $652K
- Providers
- 1,084
- Transactions
- 2,521
- Average per transaction
- $258
The per-transaction average — $258 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,084 providers the average total is $601, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. | $651,580 | 100.0% |